logo
China Fund Beats 97% of Peers by Buying Pop Mart, Dumping Moutai

China Fund Beats 97% of Peers by Buying Pop Mart, Dumping Moutai

Mint17 hours ago

A 30-year old Chinese fund manager is trouncing peers this year with a portfolio stocked with Gen Z-favored names like Pop Mart International Group, betting that new-age shopping trends can help his fund overcome the country's economic sluggishness.
Xie Tianyuan's Penghua Selected Return Flexible Allocation Mixed Fund has returned 24% this year, ranking in the top 3% among roughly 2,300 peers, data from fund tracker East Money Information Co. show. That's a turnaround from its recent past when holdings in traditional sectors like alcoholic beverages and farming dragged performance. A gauge for Chinese stocks listed in Hong Kong has risen 20% this year.
The Shenzhen-based fund manager, who took over early 2024, wasted little time in replacing what was then the fund's top holding Kweichow Moutai Co., a baijiu distiller, with the maker of smash-hit Labubu dolls, Pop Mart.
His repositioning for the fund, which has about $7 million in assets under management, reflects how cultural shifts — brought on by digital influence and youth spending — are creating opportunities for Chinese investors navigating broader challenges in the world's second-largest economy.
His conviction strengthened after witnessing the popularity of the toy maker's products in Thailand, which, he says, signaled 'non-linear growth with every metric showing breakout potential.'
Growing up immersed in Japanese anime culture — his desk is adorned with Dragon Ball Z figurines — Xie said he developed an eye for identifying promising characters or designs, called 'IP brands,' by mixing personal fandom and online research. That he himself is demographically a member of Generation Z, the driving force behind China's new 'emotional spending' consumption trend, helps him understand what may resonate beyond advertising and go viral.
'Opportunities in the sector in the years to come will be on the single stock level as the population dividend comes to an end,' he said. 'I pick companies that have breakthrough products, new business models and innovative sales channels — products that are both visually appealing and fun.'
His top pick, Pop Mart, accounted for 10.5% of the fund's total assets as of March, the top end of its maximum ownership in a single stock allowed, filings show. Other big bets include Mao Geping Cosmetics Co., up 83% this year, as well as Chongqing Baiya Sanitary Products Co., and Yantai China Pet Foods Co.
Xie's strategy lies firmly in targeting the Gen Z consumption trend, where purchase decisions are driven by emotional triggers and hobby interest. Despite looming threats from Donald Trump's proposed tariff hikes, this behavioral change fueled rallies in pockets of China's stock market, especially after the momentum from artificial intelligence began to fade.
Shares of the companies at the heart of this trend — including Pop Mart and Laopu Gold Co., known for distinctive gold pendants — have staged wild gains this year. Laopu is up more than 2,000% since its initial public offering in Hong Kong a year ago.
READ: Labubu's Mega Markups Make Pop Mart a $43 Billion Export Giant
The rally has expanded to include sectors like medical aesthetics, pet foods and even vape products. Another potential area for Xie: tapping into the rising popularity of sparkling yellow wine.
'The line between what is considered 'old' and 'new' consumption is blurring and more companies will join the new consumption pool once they realize that there's no future for them eking out a survival in their comfort zones,' Xie said. 'Even old trees can sprout new shoots.'
Still, the consumption-driven rally is showing cracks. Pop Mart tumbled after a People's Daily commentary on June 20 that called for stricter regulation of 'blind-box' toys — products in sealed packaging designed to conceal content and induce surprise and greater desire to collect them. Laopu faces greater selling pressure after the lock-up period from its IPO expired Friday.
Meanwhile, many Gen Z stocks are near or above their average price targets, and in turn, driving analysts to constantly find reasons to bump up their outlook.
Xie acknowledged that valuations in the sector may be getting ahead of fundamentals, with some stocks already pricing in earnings three to five years ahead.
Still, he remains overall bullish, particularly on the stocks he's heavily invested in.
'The gains may look incomprehensible to some people, but it's actually all rooted in earnings,' he says. 'Growth for some is underestimated, while others are just in the early stages of their life cycle.'
This article was generated from an automated news agency feed without modifications to text.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

VinFast partners with myTVS for pan-India aftersales service ahead of EV launch
VinFast partners with myTVS for pan-India aftersales service ahead of EV launch

New Indian Express

time12 minutes ago

  • New Indian Express

VinFast partners with myTVS for pan-India aftersales service ahead of EV launch

Vietnamese electric vehicle (EV) major VinFast, which is all set to enter the Indian market, has formed a service collaboration with Chennai-based multi-brand aftermarket chain myTVS, a part of the TVS Mobility group. VinFast aims to establish 120 Extended Service Workshops by partnering with potential service providers to boost its aftersales operations across India. Under this strategic collaboration, myTVS will ensure VinFast Customers receive comprehensive service coverage across India. The association focuses on delivering exceptional service quality through workshops equipped with genuine parts, advanced diagnostic and repair equipment, and highly trained technical personnel. 'This strategic collaboration with myTVS to expand our comprehensive after-sales service network demonstrates our long-term commitment to the Indian market and our dedication to customer satisfaction,' said Pham Sanh Chau, CEO, VinFast Asia. The electric carmaker is likely to enter the Indian market by the end of July 2025. As per report, the launch schedule for VinFast's electric SUVs has been postponed by about one month due to insufficient sales network development. Manufacturing operations at Vinfast's Tamil Nadu facility, initially planned to commence on June 30, have been rescheduled to July 30. Last week, VinFast announced plans to showcase its premium electric SUV models, the VF 7 and VF 6, across 11 states and cities in India. Natarajan Srinivasan, CEO, myTVS, said, 'We are confident that this unique partnership will enable VinFast to scale growth backed by our technology powered after-sales service platform. This partnership also validates the myTVS business model of building and delivering a high-quality, convenient, transparent and digitally powered after-market service platform to support the ambitions of India's automobile sector.'

Foreign banks offer Torrent ₹20,000 cr credit line for JB Chemicals buyout
Foreign banks offer Torrent ₹20,000 cr credit line for JB Chemicals buyout

Business Standard

time43 minutes ago

  • Business Standard

Foreign banks offer Torrent ₹20,000 cr credit line for JB Chemicals buyout

The Ahmedabad-based pharmaceutical firm plans to draw down the facility depending on the subscription to its upcoming open offer, the person said, requesting anonymity Mumbai The Torrent group has secured a credit line of up to ₹20,000 crore from a consortium of international lenders, including HSBC, Standard Chartered Bank, and Barclays, to fund its proposed acquisition of JB Chemicals & Pharmaceuticals Ltd, according to a person familiar with the matter. The Ahmedabad-based pharmaceutical firm plans to draw down the facility depending on the subscription to its upcoming open offer, the person said, requesting anonymity. The interest rate on the credit line has been set at a competitive 8 per cent, the person added. Sudhir Menon, chief financial officer at Torrent Pharmaceuticals, told analysts that the

KKR's exit from JB Chemicals cements its healthcare track record
KKR's exit from JB Chemicals cements its healthcare track record

Business Standard

time44 minutes ago

  • Business Standard

KKR's exit from JB Chemicals cements its healthcare track record

KKR & Co's ₹11,900 crore ($1.42 billion) exit from JB Chemicals and Pharmaceuticals marks another successful bet in India's fast-growing healthcare sector, underscoring the US-based private equity giant's strong track record in the space. KKR exited JB Chemicals on Sunday. The sale of its 46.39 per cent stake in JB Chemicals to Torrent Pharmaceuticals comes over four years after KKR acquired control of the company in 2020. The exit follows its blockbuster five-time (5x) return in Max Healthcare in 2022, which remains the largest block deal by a private equity firm in India to date, a person familiar with the matter said. In JB Chemicals, the US-based firm made 36 per cent gross internal rate of return in the exit, including sale of part of its stake via block deal early this year. The JB Chemicals deal adds to KKR's expanding healthcare portfolio in India, which includes stakes in Healthcare Global Enterprises, Baby Memorial Hospital (BMH), Healthium Medtech, and Infinx Healthcare, a US-based healthcare technology firm focused on revenue cycle and patient access solutions. Since the start of 2024, KKR's private equity arm has deployed $2 billion in India. In June, the firm arranged $600 million in financing for the Manipal group through KKR Capital Markets. The deal, anchored by KKR's private credit and insurance platforms, is aimed at supporting Manipal's long-term growth strategy. The Manipal group, which operates Manipal Health Enterprises, one of India's largest multispecialty hospital chains, has been active in the M&A (mergers and acquisitions) market. Manipal had in April 2023 sold a significant stake in its hospital business to Singapore's Temasek Holdings in a transaction valued at nearly $2 billion. KKR's back-to-back healthcare bets come amid rising investor appetite for India's healthcare sector, fuelled by growing demand for quality care, rising incomes, and increased insurance penetration. In 2024, healthcare funding saw an 80 per cent rise in deal volumes, with notable activity in medtech and single-specialty hospitals. The IT/ITeS sector deal value grew 300 per cent, driven by major transactions such as Perficient ($3 billion), Altimetrik ($900 million), and GeBBS ($865 million). Single-specialty hospitals saw particular interest, with deal volumes doubling as investors targeted underpenetrated categories such as eyecare, oncology, and IVF, as per a report by Bain & Company.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store